Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals

Bibliography

• Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006;111(1):224-59
   PubMed Web of Science ®Google Scholar
• Lundh H, Thesleff S. The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals. Eur J Pharmacol 1977;42(4):411-2
   PubMed Web of Science ®Google Scholar
• Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985;328(2):358-61
   PubMed Web of Science ®Google Scholar
• Kirsch GE, Drewe JA. Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels. J Gen Physiol 1993;102(5):797-816
   PubMed Web of Science ®Google Scholar
• Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77(2):553-62
   PubMed Web of Science ®Google Scholar
• Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994;51(3):292-6
   PubMed Web of Science ®Google Scholar
• Schwid SR, Petrie MD, McDermott MP, Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48(4):817-21
   PubMed Web of Science ®Google Scholar
• Goodman AD, Cohen JA, Cross A, Fampridine-SR in multiple sclerosis: a randomized, double blind, placebo-controlled, dose-ranging study. Mult Scler 2007;13:357-68
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Cohen JA, Dose-comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134-41
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Krupp LB, Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373(9665):732-8
   PubMed Web of Science ®Google Scholar
• Bever CT Jr, Young D, Anderson PA, The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994;44(6):1054-9
   PubMed Web of Science ®Google Scholar
• Vollmer T, Blight AR, Henney H. Steady-state pharmacokinetics of orally administered fampridine (4-aminopyridine) sustained release tablets in subjects with multiple sclerosis. Clin Ther 2009;31(10):2215-23
   Google Scholar
• Vollmer T, Henney H. Pharmacokinetics of single administration, escalating doses of 4-aminopyridine slow release in subjects with multiple sclerosis. Clin Ther 2009;31(10):2206-14
   Google Scholar
• Amos GJ, Wettwer E, Metzger F, Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol 1996;491(Pt 1):31-50
   PubMed Web of Science ®Google Scholar
• Cordeiro JM, Spitzer KW, Giles WR. Repolarizing K+ currents in rabbit heart Purkinje cells. J Physiol 1998;508(Pt 3):811-23
   PubMed Web of Science ®Google Scholar
• Ridley JM, Milnes JT, Zhang YH, Inhibition of HERG K+ current and prolongation of the guinea-pig ventricular action potential by 4-aminopyridine. J Physiol 2003;549(Pt 3):667-72
   PubMed Web of Science ®Google Scholar
• Nattel S, Matthews C, De Blasio E, Dose-dependence of 4-aminopyridine plasma concentrations and electrophysiological effects in dogs. Potential relevance to ionic mechanisms in vivo. Circulation 2000;101:1179-84
   PubMed Web of Science ®Google Scholar
• Nerbonne JM. Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium. J Physiol 2000;525(Pt 2):285-98
   PubMed Web of Science ®Google Scholar
• Han W, Wang Z, Nattel S. A comparison of transient outward currents in canine cardiac Purkinje cells and ventricular myocytes. Am J Physiol Heart Circ Physiol 2000;279(2):H466-74
   Google Scholar
• Sridhar A, da Cunha DN, Lacombe VA, The plateau outward current in canine ventricle, sensitive to 4-aminopyridine, is a constitutive contributor to ventricular repolarization. Br J Pharmacol 2007;152(6):870-9
   PubMed Web of Science ®Google Scholar
• Isoda WC, Segal JL. Effects of 4-aminopyridine on cardiac repolarization, PR interval, and heart rate in patients with spinal cord injury. Pharmacotherapy 2003;23(2):133-6
   PubMed Web of Science ®Google Scholar
• U.S Food and Drug Administration. Guidance for industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; 2005
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline; 2006
   Google Scholar
• Smith W, Swan S, Marbury T, Single-dose pharmacokinetics of 4-aminopyridine slow release in healthy volunteers and renally impaired adults. J Clin Pharmacol (in press)
   Google Scholar
• Thomas G, Klatt B, Blight A. Effect of fampridine (4-aminopyridine) on action potential parameters in isolated dog Purkinje fibers. Arch Drug Inf (in press)
   Google Scholar
• Renganathan M, Sidach S, Blight AR. Effects of 4-aminopyridine on cloned hERG channels expressed in mammalian cells. Arch Drug Inf 2009;2:51-7
   PubMedGoogle Scholar
• Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage gated potassium channel family. Science 1995;269:92-5 Erratum in: Science 1996;272(5265):1087
   Google Scholar
• Sanguinetti M, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Keating MT. Role of delayed rectifier potassium channels in cardiac repolarisation and arrhythmias. News Physiol Sci 1997;12:152-7
   Google Scholar
• Hayes KC, Katz MA, Devane JG, Pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 2003;43(4):379-85
   PubMed Web of Science ®Google Scholar
• Hayes KC, Potter PJ, Hsieh JT, Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 2004;85(1):29-34
   PubMed Web of Science ®Google Scholar
• Van Diemen HA, Polman CH, Koetsier JC, 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 1993;16(3):195-204
   PubMed Web of Science ®Google Scholar